FDA approved rusfertide, sold as Mimrylo, on August 28, 2026. The agency announced the approval for Takeda Pharmaceuticals America, Inc. under the headline “FDA Approves First Drug of Its Kind for Polycythemia Vera, a Rare Blood Disorder.” The approved label describes rusfertide as “a synthetic cyclic peptide,” which makes this a new peptide drug approval. It is number 36 on FDA’s list of novel drug approvals for 2026.
Quick answer: What did FDA approve? A new peptide medicine, rusfertide (Mimrylo), for erythrocytosis in adults with polycythemia vera, a rare blood disorder. It is a prescription drug with a single approved use. The approval does not change how any other peptide is regulated.
This article summarizes public regulatory records. It is not medical or legal advice.
What did FDA approve?
FDA’s novel approvals list records Mimrylo (rusfertide) as approved on August 28, 2026, “to treat erythrocytosis in adults with polycythemia vera” (FDA, 2026a). FDA’s announcement names Takeda Pharmaceuticals America, Inc. as the company granted approval and says the drug “mimics hepcidin,” limiting the iron available for making new red blood cells (FDA, 2026b).
The prescribing information gives the chemistry. Its description section calls rusfertide “a hepcidin mimetic” that “is a synthetic cyclic peptide (disulfide)” isolated as an acetate salt. Its mechanism section says rusfertide “is a mimetic of the endogenous hormone hepcidin that blocks the iron transporter ferroportin” (Takeda, 2026).
Mimrylo (rusfertide) approval at a glance
| Item | Detail |
|---|---|
| Approval date | August 28, 2026 |
| Company | Takeda Pharmaceuticals America, Inc. |
| Indication | Erythrocytosis in adults with polycythemia vera |
| Molecule | Synthetic cyclic peptide, hepcidin mimetic |
| Pivotal trial | VERIFY, phase 3, 293 adults, 32 weeks |
| Review | Priority review |
| Orphan designation | Designated June 12, 2020; exclusivity end date listed as TBD |
What evidence supported the approval?
FDA cites VERIFY, a multicenter, randomized, double-blind, placebo-controlled phase 3 trial. It enrolled 293 adults who needed frequent phlebotomies, a procedure to remove blood, despite standard care. Patients were randomized one to one to Mimrylo or placebo over 32 weeks. The efficacy measure was the share of patients who did not meet criteria for phlebotomy between weeks 20 and 32. FDA reports 76.9% for Mimrylo and 32.9% for placebo (FDA, 2026b).
FDA lists injection site reactions and anemia as the most common side effects. The label’s warnings and precautions cover new or worsening thrombocytosis, a rise in blood platelets; injection-site reactions; and embryo-fetal toxicity (Takeda, 2026). Tanya Wroblewski, M.D., director of FDA’s Division of Nonmalignant Hematology, called it a “first-in-class option that has the potential to meaningfully reduce patient burden.”
What does it change, and what does it not change?
It adds an approved treatment for erythrocytosis in polycythemia vera that works by mimicking hepcidin, which FDA describes as a first of its kind. FDA’s orphan drug database lists the marketing approval on August 28, 2026, with the exclusivity end date still shown as “TBD” (FDA, 2026c).
It does not change the rules for other peptides. Approval covers one product, one sponsor and one indication. It does not affect compounding lists, research-use sales or any other compound’s status.
Who does it affect?
Prescribers and patients: clinicians treating polycythemia vera now have a prescription option in this new class. Takeda: the sponsor and orphan designation holder. Compounders, sellers and researchers: not addressed by the approval.
How does it fit the earlier history?
FDA granted rusfertide orphan designation for the treatment of polycythemia vera on June 12, 2020, to Takeda Development Center Americas, Inc. (FDA, 2026c). It is not the only peptide on FDA’s 2026 list. On July 15, 2026, FDA approved Lipfendra (enlicitide decanoate) to reduce LDL cholesterol; its label describes enlicitide as “a macrocyclic peptide that binds to PCSK9” (Merck, 2026). For background on peptide medicines, see peptide hormones, types of peptides and peptides and the FDA in 2026.
Frequently asked questions about the rusfertide approval
Is rusfertide a peptide?
Yes. Its FDA-approved label describes it as a synthetic cyclic peptide (disulfide) and a hepcidin mimetic.
What is Mimrylo approved for?
The treatment of erythrocytosis in adults with polycythemia vera.
When was it approved, and for which company?
August 28, 2026, for Takeda Pharmaceuticals America, Inc.
What to know now
- Approval: Mimrylo (rusfertide), August 28, 2026, novel drug approval number 36 of 2026.
- Use: erythrocytosis in adults with polycythemia vera.
- Molecule: synthetic cyclic peptide that mimics hepcidin.
- Evidence: phase 3 VERIFY trial, 293 adults.
What we’re watching
Label updates for Mimrylo, the orphan exclusivity end date once FDA lists it, and further peptide drug approvals on FDA’s novel approvals list.